OPKO HEALTH, INC. (OPK) Form 8-K — Aug 14, 2026
OPKO Health entered into an amendment to its July 17, 2024 Note Purchase Agreement and on August 13, 2026 issued $125 million of additional senior secured notes, disclosed under Items 1.01 and 2.03 of an 8-K filed August 14, 2026. The new notes mature on July 17, 2044 and bear interest at 3-month SOFR subject to a 4.0% per annum floor plus 7.5% per annum, matching the original agreement's terms. Quarterly interest is paid from profit share payments EirGen Pharma receives from Pfizer. The notes are secured by EirGen's royalty interest in mazdutide sales in China under a 2010 license with Eli Lilly.
Key figures
- Debt Amount
- 125000000
- Interest Rate
- 3-month SOFR (subject to 4.0% per annum floor) plus 7.5% per annum
- Maturity Date
- July 17, 2044
- Sofr Floor Percent
- 4
- Issuance Exemption
- Section 4(a)(2) of the Securities Act and Rule 144
- Interest Payable From
- Quarterly Pfizer profit share payments (Royalty Payments) received by EirGen, backstopped by Eli Lilly mazdutide royalty payments
- Mazdutide Payments Cap
- $187.5 million
- Margin Over Sofr Percent
- 7.5
- Original Agreement Date
- July 17, 2024
Price after filing
Close on the filing date to close N calendar days later (from $1.38). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.